|
**Overview**: Lipid Profile Basic Panel**Introduction**: The Lipid Profile Basic Panel is a diagnostic tool designed to assess lipid levels using serum samples. In India, dyslipidemia affects ~40-50 percent of adults (~300-400 million), a major driver of cardiovascular disease (CVD, ~28 percent of deaths), with high prevalence of high LDL/low HDL in urban and increasingly rural populations due to diet transition. High morbidity from under-screening in rural/low-SES adults with diabetes/hypertension, limited labs, delayed statin therapy leading to premature MI or stroke. Per cardiology practices aligned with ICMR, Cardiological Society of India, and NPCDCS guidelines, the test employs spectrophotometry for total cholesterol, HDL, LDL, triglycerides, VLDL, and cholesterol/HDL ratio over 1-2 days with high accuracy, valuable for risk stratification and statin initiation. This diagnostic falls under lipid screening and targets adults >40 years or with risk factors (diabetes, smoking, family CVD), addressing accurate detection to guide lifestyle modification and pharmacotherapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise lipid assessment and reducing CVD burden. Its serum-based approach ensures reliable profile measurement.**Other Names**: Lipid Basic Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Basic lipid panel standard; in India, key in NCD screening.**Purpose**: The test assesses 6 parameters including total cholesterol to guide lipid evaluation, assess CVD risk, inform statin therapy.**Test Parameters**: 1. Total Cholesterol, 2. HDL, 3. LDL, 4. Triglycerides, 5. VLDL, 6. Cholesterol/HDL Ratio.**Pretest Condition**: Fasting 10-12 hours required; patients should report CVD risk factors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on diabetes, hypertension, family CVD.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated dyslipidemia including MI/stroke, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High LDL/triglycerides/low HDL indicate high CVD risk, necessitating specialist input.**Specialist Consultation**: Cardiologists or physicians should be consulted for management.**Additional Supporting Tests**: hsCRP, apoB for confirmation.**Test Limitations**: Fasting critical; comprehensive approach required.**References**: Indian Journal of Community Medicine 2024, CVD Studies India 2023. |
